Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tam, Constantine S., Kantarjian, Hagop, Garcia-Manero, Guillermo, Borthakur, Gautam, O'Brien, Susan, Ravandi, Farhad, Shan, Jenny, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082324/
https://ncbi.nlm.nih.gov/pubmed/18492956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141580
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados